PMID- 35254329
OWN - NLM
STAT- MEDLINE
DCOM- 20220421
LR  - 20231031
IS  - 1473-5636 (Electronic)
IS  - 0960-8931 (Linking)
VI  - 32
IP  - 2
DP  - 2022 Apr 1
TI  - Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients 
      with melanoma: a systemic review and meta-analysis.
PG  - 71-78
LID - 10.1097/CMR.0000000000000800 [doi]
AB  - The purpose of this study is to review the efficacy of radiotherapy combined with 
      immune checkpoint inhibitors (ICIs) in the treatment of melanoma and 
      systematically evaluate the efficacy and safety of this combined treatment 
      compared with ICIs alone. We searched a number of online databases up to 1 July 
      2021. Comprehensive Meta-Analysis 2.0 and RevMan 5.0 were used for summary 
      analysis. The overall survival (OS), progression-free survival (PFS), overall 
      response rate (ORR) and treatment adverse effects (AEs) were calculated. In 
      total, 624 patients were included from 12 studies, including nine published 
      studies and the results of three clinical trials. Radiotherapy combined with ICIs 
      had a higher ORR compared with ICIs alone (35.00 vs. 20.39%). In terms of 
      survival effect, radiotherapy combined with ICIs had no obvious advantage in OS. 
      There was no statistically significant difference between 6-month and 12-month OS 
      (P = 0.13; P = 0.69). There was no significant difference in PFS at 6 months 
      (P = 0.08), but there was a significant difference in PFS at 12 months 
      (P = 0.005). For patients with melanoma, radiotherapy combined with ICIs can 
      improve the effective rate of treatment. Although there is no obvious OS 
      advantage, it can improve PFS without serious adverse effects. Most of the 
      studies included in this article are retrospective analyses, and there are few 
      randomized controlled studies at present. Therefore, more prospective studies are 
      still needed to explore the efficacy of radiotherapy combined with immunotherapy 
      in melanoma.
CI  - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Yin, Gaofei
AU  - Yin G
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, Beijing Tongren 
      Hospital, Capital Medical University, Beijing, China.
FAU - Guo, Wei
AU  - Guo W
FAU - Huang, Zhigang
AU  - Huang Z
FAU - Chen, Xiaohong
AU  - Chen X
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - England
TA  - Melanoma Res
JT  - Melanoma research
JID - 9109623
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - Humans
MH  - Immune Checkpoint Inhibitors/pharmacology/therapeutic use
MH  - Immunotherapy/methods
MH  - *Melanoma/drug therapy/radiotherapy
MH  - Retrospective Studies
MH  - *Skin Neoplasms/drug therapy/radiotherapy
EDAT- 2022/03/08 06:00
MHDA- 2022/04/22 06:00
CRDT- 2022/03/07 12:16
PHST- 2022/03/07 12:16 [entrez]
PHST- 2022/03/08 06:00 [pubmed]
PHST- 2022/04/22 06:00 [medline]
AID - 00008390-202204000-00001 [pii]
AID - 10.1097/CMR.0000000000000800 [doi]
PST - ppublish
SO  - Melanoma Res. 2022 Apr 1;32(2):71-78. doi: 10.1097/CMR.0000000000000800.